Ken Griffin Arvinas, Inc. Put Options Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2025 May 15, 2025	BUY	$7.02 - $20.5 $1.18 Million - $3.45 Million	168,500 Added 299.29%	224,800 $1.58 Million
Q4 2024 Feb 14, 2025	BUY	$17.83 - $28.04 $691,803 - $1.09 Million	38,800 Added 221.71%	56,300 $1.08 Million
Q3 2024 Nov 14, 2024	BUY	$23.66 - $32.73 $94,640 - $130,919	4,000 Added 29.63%	17,500 $431,000
Q2 2024 Aug 14, 2024	SELL	$24.46 - $40.4 $430,496 - $711,040	-17,600 Reduced 56.59%	13,500 $359,000
Q1 2024 May 15, 2024	BUY	$36.38 - $52.31 $774,894 - $1.11 Million	21,300 Added 217.35%	31,100 $1.28 Million
Q4 2023 Feb 14, 2024	SELL	$14.19 - $42.33 $15,609 - $46,563	-1,100 Reduced 10.09%	9,800 $403,000
Q3 2023 Nov 14, 2023	BUY	$19.64 - $28.21 $7,856 - $11,284	400 Added 3.81%	10,900 $214,000
Q2 2023 Aug 14, 2023	SELL	$21.73 - $31.43 $171,667 - $248,297	-7,900 Reduced 42.93%	10,500 $260,000
Q1 2023 May 15, 2023	SELL	$26.15 - $37.26 $2.02 Million - $2.88 Million	-77,300 Reduced 80.77%	18,400 $502,000
Q4 2022 Feb 14, 2023	BUY	$32.47 - $57.24 $3.11 Million - $5.48 Million	95,700 New	95,700 $3.27 Million

242

59.2M

2.65M

1.1M

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $333M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.